Articles

1. Population Pharmacokinetics of Intravenous Lidocaine in Adults: A Systematic Review

   • Keng Wah Foong
   • Sook Hui Chaw
   • Pui San Loh

   Systematic Review 04 May 2024

   

2. Correction: Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

   • Lisanne A. H. Bevers
   • Anne E. M. Kamphuis
   • Angela Colbers

   Correction Open access 02 May 2024

3. Development of a Weight-Band Dosing Approach for Vosoritide in Children with Achondroplasia Using a Population Pharmacokinetic Model

   • Yulan Qi
   • Ming Liang Chan
   • Joshua Henshaw

   Original Research Article Open access 23 April 2024

   

4. Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents

   • Conor J. O’Hanlon
   • Anita Sumpter
   • Jacqueline A. Hannam

   Original Research Article Open access 13 April 2024

   

5. Clinical Pharmacology of the Antibody–Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors

   • Mei Tang
   • Amit Garg
   • Srinivasu Poondru

   Review Article Open access 12 April 2024 Pages: 423 - 438

   

6. Pharmacokinetics of Monoclonal Antibodies Throughout Pregnancy: A Systematic Literature Review

   • J. van Gendt
   • R. Emaus
   • Paola Mian

   Systematic Review Open access 07 April 2024

   

7. Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration

   • Julia E. M. van Dommelen
   • Heleen Grootjans
   • Maaike A. Sikma

   Original Research Article Open access 06 April 2024

   

8. Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors

   • Abhishek G. Sathe
   • Indrajeet Singh
   • Ahmed A. Othman

   Original Research Article Open access 05 April 2024

   

9. Comment on “Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies” and “High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints”

   • Leping Kong
   • Jan-Willem C. Alffenaar
   • Sophie L. Stocker

   Letter to the Editor 04 April 2024

10. Relative Bioavailability of Dolutegravir (DTG) and Emtricitabine/Tenofovir Alafenamide Fumarate (F/TAF) Administered as Paediatric Tablet Formulations in Healthy Volunteers

    • Lisanne A. H. Bevers
    • Anne E. M. Kamphuis
    • Angela Colbers

    Original Research Article Open access 04 April 2024

    

11. Have We Neglected to Study Target-Site Drug Exposure in Children? A Systematic Review of the Literature

    • Eline Hermans
    • Jozefien Meersschaut
    • Pieter A. De Cock

    Systematic Review 29 March 2024 Pages: 439 - 468

    

12. Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling

    • Krina Mehta
    • Pavel Balazki
    • J. G. Coen van Hasselt

    Original Research Article Open access 26 March 2024

    

13. Personalized Antifungal Therapy Through Model-Informed Precision Dosing of Posaconazole

    • Anouk M. E. Jansen
    • Kim Snijdelaar
    • Rob ter Heine

    Original Research Article Open access 26 March 2024

    

14. Population Pharmacodynamic Dose–Response Analysis of Serum Potassium Following Dosing with Sodium Zirconium Cyclosilicate

    • Robert C. Penland
    • Magnus Åstrand
    • Mats Någård

    Original Research Article Open access 19 March 2024 Pages: 551 - 560

    

15. Optimization of Ganciclovir and Valganciclovir Starting Dose in Children by Machine Learning

    • Laure Ponthier
    • Julie Autmizguine
    • Jean-Baptiste Woillard

    Original Research Article 16 March 2024 Pages: 539 - 550

    

16. Performance of Eight Infliximab Population Pharmacokinetic Models in a Cohort of Dutch Children with Inflammatory Bowel Disease

    • Nanja C. Bevers
    • Ron J. Keizer
    • Patrick F. van Rheenen

    Original Research Article Open access 15 March 2024 Pages: 529 - 538

    

17. Clinical Pharmacokinetics and Pharmacodynamics of Naloxone

    • Teijo I. Saari
    • John Strang
    • Ola Dale

    Review Article Open access 14 March 2024 Pages: 397 - 422

    

18. Toward Genetic Testing of Rivaroxaban? Insights from a Systematic Review on the Role of Genetic Polymorphism in Rivaroxaban Therapy

    • Yi Ma
    • Zaiwei Song
    • Zhanmiao Yi

    Systematic Review 09 March 2024 Pages: 279 - 291

    

19. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation

    • Alex Yu
    • Anasuya Hazra
    • Alberto Russu

    Original Research Article Open access 04 March 2024 Pages: 511 - 527

    

20. Dosing of Convalescent Plasma and Hyperimmune Anti-SARS-CoV-2 Immunoglobulins: A Phase I/II Dose-Finding Study

    • Sammy Huygens
    • Tim Preijers
    • Bart J. A. Rijnders

    Original Research Article Open access 01 March 2024 Pages: 497 - 509

    

21. Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration

    • Joseph Piscitelli
    • Micaela B. Reddy
    • Jason H. Williams

    Original Research Article Open access 29 February 2024 Pages: 483 - 496

    

22. Bayesian Vancomycin Model Selection for Therapeutic Drug Monitoring in Neonates

    • Dua’a Alrahahleh
    • Yann Thoma
    • Jan-Willem Alffenaar

    Original Research Article Open access 28 February 2024 Pages: 367 - 380

    

23. A Population Pharmacokinetic Analysis of l-Glutamine Exposure in Patients with Sickle Cell Disease: Evaluation of Dose and Food Effects

    • Alina Sadaf
    • Min Dong
    • Charles T. Quinn

    Original Research Article Open access 24 February 2024 Pages: 357 - 365

    

24. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers

    • Brit S. Rohr
    • Evelyn Krohmer
    • Walter E. Haefeli

    Original Research Article Open access 23 February 2024 Pages: 469 - 481

    

25. Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm

    • Yeamin Huh
    • Jessica Wojciechowski
    • Vivek S. Purohit

    Original Research Article Open access 15 February 2024 Pages: 381 - 394

    

26. Towards More Robust Evaluation of the Predictive Performance of Physiologically Based Pharmacokinetic Models: Using Confidence Intervals to Support Use of Model-Informed Dosing in Clinical Care

    • Marjolein D. van Borselen
    • Laurens Auke Æmiel Sluijterman
    • Saskia N. de Wildt

    Original Research Article Open access 15 February 2024 Pages: 343 - 355

    

27. Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy

    • Naïm Bouazza
    • Saïk Urien
    • Isabelle Sermet-Gaudelus

    Original Research Article 04 February 2024 Pages: 333 - 342

    

28. Reporting Coefficient of Variation for Logit, Box-Cox and Other Non-log-normal Parameters

    • John P. Prybylski

    Commentary 01 February 2024 Pages: 133 - 135

29. Salivary Therapeutic Drug Monitoring of Antimicrobial Therapy: Feasible or Futile?

    • Lina Davies Forsman
    • Hannah Yejin Kim
    • Jan-Willem C. Alffenaar

    Current Opinion Open access 01 February 2024 Pages: 269 - 278

30. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Moderate-to-Severe Psoriasis

    • Jonathan Greenzaid
    • Steven Feldman

    Review Article 27 January 2024 Pages: 137 - 153

    

31. Maternal Ezetimibe Concentrations Measured in Breast Milk and Its Use in Breastfeeding Infant Exposure Predictions

    • Cindy H. T. Yeung
    • Julie Autmizguine
    • Andrea N. Edginton

    Original Research Article 26 January 2024 Pages: 317 - 332

    

32. Population Pharmacokinetic/Pharmacodynamic Models for P2Y12 Inhibitors: A Systematic Review and Clinical Appraisal Using Exposure Simulation

    • Jingcheng Chen
    • Yuchen Qu
    • Dongyang Liu

    Original Research Article 20 January 2024 Pages: 303 - 316

    

33. Use of Pharmacokinetic and Pharmacodynamic Data to Develop the CDK4/6 Inhibitor Ribociclib for Patients with Advanced Breast Cancer

    • Yan Ji
    • Hilmar Schiller
    • Abhijit Chakraborty

    Review Article Open access 20 January 2024 Pages: 155 - 170

    

34. Comment on: Anti-Coagulant Treatment of Cancer-Associated Thrombosis in Frail Patients: Impact of Frailties on the Management of Drug–Drug Interactions

    • Lorenz Van der Linden
    • Thomas Vanassche
    • Peter Verhamme

    Letter to the Editor 18 January 2024 Pages: 395 - 396

35. Population Pharmacokinetic Modeling of Cotadutide: A Dual Agonist Peptide of Glucagon-Like Peptide and Glucagon Receptors Administered to Participants with Type II Diabetes Mellitus, Chronic Kidney Disease, Obesity and Non-Alcoholic Steatohepatitis

    • Hongtao Yu
    • Magnus Åstrand
    • Anis A. Khan

    Original Research Article 18 January 2024 Pages: 255 - 267

    

36. Pharmacokinetics, Disposition, and Biotransformation of [¹⁴C]Lenacapavir, a Novel, First-in-Class, Selective Inhibitor of HIV-1 Capsid Function, in Healthy Participants Following a Single Intravenous Infusion

    • Elijah Weber
    • Raju Subramanian
    • Renu Singh

    Original Research Article 18 January 2024 Pages: 241 - 253

    

37. Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study

    • Yuru Fan
    • Xuan Zhang
    • Wei Hu

    Original Research Article 10 January 2024 Pages: 293 - 302

    

38. Pharmacokinetics, Pharmacodynamics, and Safety of Single Dose HSK7653 Tablets in Chinese Subjects with Normal or Impaired Renal Function

    • Dan Shi
    • Lin Chen
    • Dongliang Zhang

    Original Research Article 06 January 2024 Pages: 227 - 239

    

39. Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action

    • K. P. van Rhee
    • C. A. J. Knibbe
    • R. J. M. Brüggemann

    Current Opinion Open access 05 January 2024 Pages: 1 - 12

    

40. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir

    • Jacqueline Gerhart
    • Donna S. Cox
    • Bharat Damle

    Review Article Open access 04 January 2024 Pages: 27 - 42

    

41. Factors Influencing Unfractionated Heparin Pharmacokinetics and Pharmacodynamics During a Cardiopulmonary Bypass

    • Audrick Gibert
    • Julien Lanoiselée
    • Edouard Ollier

    Original Research Article 02 January 2024 Pages: 211 - 225

    

42. Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

    • Maddalena Centanni
    • Mirjam E. van de Velde
    • Lena E. Friberg

    Original Research Article Open access 23 December 2023 Pages: 197 - 209

    

43. Toward Model-Based Informed Precision Dosing of Vancomycin in Hematologic Cancer Patients: A First Step

    • Jessica Le Blanc
    • Denis Projean
    • Amélie Marsot

    Original Research Article 21 December 2023 Pages: 183 - 196

    

44. Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

    • Joseph Chen
    • Alessandra Bearz
    • Yazdi K. Pithavala

    Original Research Article Open access 11 December 2023 Pages: 171 - 182

    

45. Impact of Key Components of Intensified Ceftaroline Dosing on Pharmacokinetic/Pharmacodynamic Target Attainment

    • Iris K. Minichmayr
    • Sebastian G. Wicha
    • Markus Zeitlinger

    Original Research Article Open access 26 November 2023 Pages: 121 - 131

    

46. Digoxin Pharmacokinetics in Patients with Obesity Before and After a Gastric Bypass or a Strict Diet Compared with Normal Weight Individuals

    • Kine Eide Kvitne
    • Markus Hovd
    • Ida Robertsen

    Original Research Article Open access 22 November 2023 Pages: 109 - 120

    

47. Acknowledgement to Referees

    Acknowledgement to Referees 22 November 2023 Pages: 1655 - 1660

48. Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China

    • Ling Song
    • Fangrui Cao
    • Dongyang Liu

    Original Research Article 20 November 2023 Pages: 93 - 108

    

49. How to Dose Vancomycin in Overweight and Obese Patients with Varying Renal (Dys)function in the Novel Era of AUC 400–600 mg·h/L-Targeted Dosing

    • Tan Zhang
    • Elke H. J. Krekels
    • Catherijne A. J. Knibbe

    Original Research Article Open access 16 November 2023 Pages: 79 - 91

    

50. Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antifungal Agents: A Review

    • Theresa Pecho
    • Markus Zeitlinger

    Review Article Open access 16 November 2023 Pages: 13 - 26